{
    "clinical_study": {
        "@rank": "26839", 
        "arm_group": [
            {
                "arm_group_label": "DW-1030(eperisone HCl) 75mg BID", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Myonal Tab.(eperisone HCl) 50mg TID", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this clinical study is to determine whether or not DW-1030 is not inferior to\n      eperisone HCl in efficacy and safety."
        }, 
        "brief_title": "Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients", 
        "condition": "Acute Back Pain", 
        "condition_browse": {
            "mesh_term": "Back Pain"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult males/Females aged over 18 years\n\n          -  Patients with symptom of Acute skeletomuscle myospasm and Back pain\n\n          -  Patients with Pain VAS Value over 40 mm in Visit 2\n\n          -  Subjects who voluntarily or legal guardian agreed with written consent\n\n        Exclusion Criteria:\n\n          -  Patients with Back pain caused by spinal spondylosis, spinal stenosis, fractures,\n             cancer, severe arthritis, osteoporosis, sciatica, infection\n\n          -  Muscular patients such as myositis, muscular atrophy disease, increased muscle tone,\n             myasthenia gravis\n\n          -  Patients who had taken invasive procedures such as epidural injections or spinal\n             stimulation to cure the back pain within 6 months from the screening point\n\n          -  Patients who had taken passive physical therapy or ionphoresis within 12 hours from\n             the screening point\n\n          -  Patients with severe GI tract disorder, heart disease, hypertension\n\n          -  Patients who had taken NSAIDS within 24hours from the screening point"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "January 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040415", 
            "org_study_id": "DW-1030_301"
        }, 
        "intervention": [
            {
                "arm_group_label": "DW-1030(eperisone HCl) 75mg BID", 
                "intervention_name": "DW-1030(eperisone HCl) 75mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Myonal Tab.(eperisone HCl) 50mg TID", 
                "intervention_name": "Myonal Tab.(eperisone HCl) 50mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Myonal Tab.(eperisone HCl) 50mg TID", 
                "intervention_name": "Placebo drug of DW-1030", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "DW-1030(eperisone HCl) 75mg BID", 
                "intervention_name": "Placebo drug of Myonal Tab.", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Eperisone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 17, 2014", 
        "official_title": "A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase Lll Clinical Trial to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Changes of Finger-to-Floor Distance(FFD) compared to baseline 7days after administration", 
            "time_frame": "1, 3, 7 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040415"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Changes of 100mm Pain VAS", 
                "time_frame": "-3, 1, 3, 7 day"
            }, 
            {
                "measure": "Oswestry Disability Index (ODI)", 
                "time_frame": "1, 3, 7 day"
            }, 
            {
                "measure": "Physician's Global Assessment", 
                "time_frame": "7 day"
            }, 
            {
                "measure": "The number of using rescue drugs and the total amount", 
                "time_frame": "1, 3, 7 days"
            }
        ], 
        "source": "Daewon Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daewon Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}